查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1975007

全球HER2乳癌篩檢市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global HER2 Breast Cancer Test Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 112 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計 HER2乳癌篩檢市場將從 2025 年的 4.3396 億美元成長到 2034 年的 7.8185 億美元，2026 年至 2034 年的複合年成長率為 6.76%。

由於全球乳癌發生率不斷上升以及早期診斷的重要性日益凸顯，全球HER2乳癌檢測市場正顯著擴張。 HER2檢測在製定標靶治療策略方面發揮至關重要的作用，尤其對於可能受益於HER2標靶治療的患者。免疫組化和現場雜合反應等先進診斷技術的日益普及進一步推動了市場需求。醫療機構越來越重視精準診斷，以提高存活率和治療效果。

市場成長主要得益於篩檢項目的擴展、檢查室基礎設施的改善以及患者對基因和生物標記檢測認知度的提高。 HER2標靶治療的進展進一步增加了對準確可靠檢測解決方案的需求。政府對癌症研究的支持以及診斷檢測的報銷政策也促進了檢測技術的廣泛應用。此外，技術創新正在提升臨床檢查室的檢測準確性、縮短檢測週期並提高自動化程度。

由於分子診斷和數位病理學的進步，HER2乳癌檢測市場預計將進一步成長。將人工智慧融入診斷流程可望進一步提高準確性和效率。在新興市場，隨著醫療保健服務的改善，預計檢測的普及率將進一步提高。隨著個人化醫療不斷影響癌症治療，HER2檢測仍將是全球乳癌管理策略的關鍵組成部分。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球HER2乳癌檢測市場：依檢測類型分類

  • 市場分析、洞察與預測
  • 免疫組織化學（IHC）
  • 螢光/顯色位點雜合反應（FISH/CISH）

第5章：全球HER2乳癌篩檢市場：依最終用戶分類

  • 市場分析、洞察與預測
  • 醫院
  • 診斷檢查室
  • 其他

第6章：全球HER2乳癌檢測市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第7章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第8章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Abbott Molecular Inc
    • Biogenex Laboratories Inc
    • Leica Biosystems
    • Roche
    • Agilent Technologies
    • Mylab Discovery Solutions Pvt. Ltd
    • Jiangsu HengRui Medicine Co.Ltd
    • Shanghai Henlius Biotech
    • Merus NV
    • GeneQuantum
簡介目錄
Product Code: VMR112111511

The HER2 Breast Cancer Test Market size is expected to reach USD 781.85 Million in 2034 from USD 433.96 Million (2025) growing at a CAGR of 6.76% during 2026-2034.

The Global HER2 Breast Cancer Test Market is expanding significantly due to the growing incidence of breast cancer worldwide and the rising importance of early diagnosis. HER2 testing plays a critical role in determining targeted treatment strategies, particularly for patients who may benefit from HER2-directed therapies. Increasing adoption of advanced diagnostic technologies such as immunohistochemistry and in situ hybridization is strengthening market demand. Healthcare providers are increasingly emphasizing precision diagnostics to improve survival rates and treatment effectiveness.

Market growth is driven by the expansion of screening programs, improved laboratory infrastructure, and rising awareness among patients about genetic and biomarker testing. Pharmaceutical advancements in HER2-targeted therapies are further increasing the need for accurate and reliable testing solutions. Government support for cancer research and reimbursement policies for diagnostic testing are also encouraging broader adoption. Additionally, technological innovations are enhancing test accuracy, turnaround time, and automation in clinical laboratories.

In the future, the HER2 Breast Cancer Test Market is expected to benefit from advancements in molecular diagnostics and digital pathology. The integration of artificial intelligence in diagnostic workflows may further improve accuracy and efficiency. Emerging markets are likely to witness increased testing adoption due to improving healthcare access. As personalized medicine continues to shape oncology treatment, HER2 testing will remain a critical component of breast cancer management strategies worldwide.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

  • Immunohistochemistry (IHC)
  • Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH)

By End-user

  • Hospitals
  • Diagnostic Laboratories
  • Others

COMPANIES PROFILED

  • Abbott Molecular Inc, Biogenex Laboratories Inc, Leica Biosystems, Roche, Agilent Technologies, Mylab Discovery Solutions Pvt Ltd, Jiangsu HengRui Medicine Co, Ltd, Shanghai Henlius Biotech, Merus NV, GeneQuantum
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HER2 BREAST CANCER TEST MARKET: BY TEST TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Test Type
  • 4.2. Immunohistochemistry (IHC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Fluorescence/Chromogenic In Situ Hybridization (FISH/CISH) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HER2 BREAST CANCER TEST MARKET: BY END-USER 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast End-user
  • 5.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Diagnostic Laboratories Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HER2 BREAST CANCER TEST MARKET: BY REGION 2022-2034(USD MN)

  • 6.1. Regional Outlook
  • 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.2.1 By Test Type
    • 6.2.2 By End-user
    • 6.2.3 United States
    • 6.2.4 Canada
    • 6.2.5 Mexico
  • 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.3.1 By Test Type
    • 6.3.2 By End-user
    • 6.3.3 United Kingdom
    • 6.3.4 France
    • 6.3.5 Germany
    • 6.3.6 Italy
    • 6.3.7 Russia
    • 6.3.8 Rest Of Europe
  • 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.4.1 By Test Type
    • 6.4.2 By End-user
    • 6.4.3 India
    • 6.4.4 Japan
    • 6.4.5 South Korea
    • 6.4.6 Australia
    • 6.4.7 South East Asia
    • 6.4.8 Rest Of Asia Pacific
  • 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.5.1 By Test Type
    • 6.5.2 By End-user
    • 6.5.3 Brazil
    • 6.5.4 Argentina
    • 6.5.5 Peru
    • 6.5.6 Chile
    • 6.5.7 South East Asia
    • 6.5.8 Rest of Latin America
  • 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 6.6.1 By Test Type
    • 6.6.2 By End-user
    • 6.6.3 Saudi Arabia
    • 6.6.4 UAE
    • 6.6.5 Israel
    • 6.6.6 South Africa
    • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

  • 7.1. Recent Developments
  • 7.2. Company Categorization
  • 7.3. Supply Chain & Channel Partners (based on availability)
  • 7.4. Market Share & Positioning Analysis (based on availability)
  • 7.5. Vendor Landscape (based on availability)
  • 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL HER2 BREAST CANCER TEST INDUSTRY

  • 8.1. Top Companies Market Share Analysis
  • 8.2. Company Profiles
    • 8.2.1 Abbott Molecular Inc
    • 8.2.2 Biogenex Laboratories Inc
    • 8.2.3 Leica Biosystems
    • 8.2.4 Roche
    • 8.2.5 Agilent Technologies
    • 8.2.6 Mylab Discovery Solutions Pvt. Ltd
    • 8.2.7 Jiangsu HengRui Medicine Co.Ltd
    • 8.2.8 Shanghai Henlius Biotech
    • 8.2.9 Merus N.V
    • 8.2.10 GeneQuantum